Published in Best Pract Res Clin Gastroenterol on February 01, 2005
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet (2010) 4.01
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol (2008) 2.24
Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 1.70
Genetics of hepatocellular carcinoma. World J Gastroenterol (2007) 1.64
HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol (2008) 1.53
Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One (2011) 1.44
Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench (2015) 1.23
Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol (2012) 1.21
Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16
Policy alternatives for treatments for rare diseases. CMAJ (2010) 1.11
Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol Lett (2013) 1.08
Antiproliferation and apoptosis induction of paeonol in HepG2 cells. World J Gastroenterol (2007) 1.07
miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest (2012) 1.07
Incidence of hepatocellular carcinoma in southeast iran. Hepat Mon (2010) 1.07
Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol (2009) 1.06
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut Liver (2016) 1.03
The role of aflatoxins in hepatocellular carcinoma. Hepat Mon (2012) 1.01
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00
Anti-proliferative and pro-apoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2. Cytotechnology (2011) 0.96
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol (2015) 0.96
Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev (2012) 0.95
Gateway to Care campaign: a public health initiative to reduce the burden of hepatitis B in Haimen City, China. BMC Public Health (2014) 0.95
Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol (2011) 0.94
Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol (2013) 0.93
Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection. Environ Health Perspect (2011) 0.91
Overexpression of endothelin 1 triggers hepatocarcinogenesis in zebrafish and promotes cell proliferation and migration through the AKT pathway. PLoS One (2014) 0.89
Aflatoxin B1 negatively regulates Wnt/β-catenin signaling pathway through activating miR-33a. PLoS One (2013) 0.89
A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res (2008) 0.88
Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol (2009) 0.88
Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish. PLoS One (2013) 0.87
Excess body mass index and risk of liver cancer: a nonlinear dose-response meta-analysis of prospective studies. PLoS One (2012) 0.85
miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. Oncotarget (2015) 0.84
Hyperthermia inhibits hypoxia-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells. World J Gastroenterol (2012) 0.84
Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics (2010) 0.83
Cancer mortality and oil production in the Amazon Region of Ecuador, 1990-2005. Int Arch Occup Environ Health (2008) 0.83
Roles of CXCL5 on migration and invasion of liver cancer cells. J Transl Med (2014) 0.83
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) (2014) 0.82
Transforming growth factor beta1 gene variation Leu10Pro affects secretion and function in hepatic cells. Dig Dis Sci (2012) 0.82
[Incidence of hepatocellular carcinoma in chronic infection with hepatitis B]. Pan Afr Med J (2015) 0.82
Cirrhosis and Chronic Viral Hepatitis as Risk Factors for Hepatocellular Carcinoma: Romanian Single-clinic Experience. Maedica (Buchar) (2010) 0.81
Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center. World J Surg (2010) 0.81
Fish intake and risk of liver cancer: a meta-analysis. PLoS One (2015) 0.81
Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient. Oncol Lett (2012) 0.80
Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol (2007) 0.79
Stimulation of sister chromatid exchanges and mutation by aflatoxin B1-DNA adducts in Saccharomyces cerevisiae requires MEC1 (ATR), RAD53, and DUN1. Mol Carcinog (2008) 0.79
Radiotherapy for multiple brain metastases from hepatocellular carcinomas. World J Gastroenterol (2007) 0.79
Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol (N Y) (2006) 0.78
A peculiar mutation spectrum emerging from young peruvian patients with hepatocellular carcinoma. PLoS One (2014) 0.78
Mutation spectrum of hepatocellular carcinoma from eastern-European patients betrays the impact of a complex exposome. J Expo Sci Environ Epidemiol (2014) 0.78
Anticancer activity of Cynodon dactylon L. root extract against diethyl nitrosamine induced hepatic carcinoma. South Asian J Cancer (2015) 0.78
Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis. J Gastrointest Oncol (2011) 0.78
From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways. World J Gastrointest Oncol (2010) 0.77
Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) (2014) 0.77
MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Oncol Lett (2015) 0.77
Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol (2016) 0.77
Aflatoxin B(1)-Associated DNA Adducts Stall S Phase and Stimulate Rad51 foci in Saccharomyces cerevisiae. J Nucleic Acids (2010) 0.77
Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World J Gastroenterol (2014) 0.77
Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting. World J Surg Oncol (2014) 0.76
Influence of limonin on Wnt signalling molecule in HepG2 cell lines. J Nat Sci Biol Med (2013) 0.76
Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
DYNA CT arteriographic evaluation of hepatocellular carcinoma for treatment by trans-catheter arterial chemoembolization. Int J Clin Exp Med (2015) 0.75
Investigation of chromosomal aberrations in Egyptian hepatocellular carcinoma patients by fluorescence in situ hybridization. Indian J Hum Genet (2010) 0.75
Hepatitis B and C viruses and survival from hepatocellular carcinoma in the Arkhangelsk region: a Russian registry-based study. Int J Circumpolar Health (2013) 0.75
Effects of cordycepin on HepG2 and EA.hy926 cells: Potential antiproliferative, antimetastatic and anti-angiogenic effects on hepatocellular carcinoma. Oncol Lett (2014) 0.75
Nuclear IKKα mediates microRNA-7/-103/107/21 inductions to downregulate maspin expression in response to HBx overexpression. Oncotarget (2016) 0.75
Hepatitis B Virus Core Promoter Double Mutations (A1762T, G1764A) Are Associated with Lower Levels of Serum Dihydrolipoyl Dehydrogenase. Intervirology (2016) 0.75
Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute. Eur J Radiol Open (2016) 0.75
Current imaging strategies of primary and secondary neoplasms of the liver. Semin Intervent Radiol (2006) 0.75
New insights on the role of epigenetic alterations in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Environmental Exposures and Hepatocellular Carcinoma. J Clin Transl Hepatol (2013) 0.75
How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis. Liver Cancer (2017) 0.75
The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis (2011) 2.96
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol (2006) 1.56
Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev (2002) 1.49
Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology (2010) 1.19
Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res (2003) 1.13
Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol (2004) 1.09
Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics (2004) 1.06
A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics (2003) 1.03
Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol (2005) 1.01
The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark (2008) 1.01
Acculturation and breast density in foreign-born, U.S. Chinese women. Cancer Epidemiol Biomarkers Prev (2006) 0.97
Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics (2009) 0.95
Blood folate levels and risk of liver damage and hepatocellular carcinoma in a prospective high-risk cohort. Cancer Epidemiol Biomarkers Prev (2007) 0.92
Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol (2011) 0.90
Chronic HBV infection outside treatment guidelines: is treatment needed? Antivir Ther (2012) 0.89
Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. Int J Cancer (2005) 0.87
Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population. Cancer Causes Control (2003) 0.83
Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis. J Clin Virol (2011) 0.82
Chronic hepatitis B infection: a workshop consensus statement and algorithm. J Fam Pract (2011) 0.81
A phylogenetic analysis identifies heterogeneity among hepatocellular carcinomas. Hepatology (2002) 0.81
Dichlorodiphenyltrichloroethane and risk of hepatocellular carcinoma. Int J Cancer (2012) 0.78
Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach. J Clin Microbiol (2011) 0.77
Hepatocellular carcinoma of the liver. Cancer Biomark (2010) 0.77
International liver cancer incidence trends--letter. Cancer Epidemiol Biomarkers Prev (2011) 0.75
Fumonisin B1 and risk of hepatocellular carcinoma in two Chinese cohorts. Food Chem Toxicol (2011) 0.75
Surrogate markers of efficacy for medical treatment of viral hepatitis. Biotechnol Healthc (2004) 0.75
The Australia antigen and role of the late Philadelphia General Hospital in reducing post-transfusion hepatitis and sequelae. Hepatology (2011) 0.75